Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2015 Feb;59(2):1347-51. doi: 10.1128/AAC.04508-14. Epub 2014 Dec 1.

Evolution of Staphylococcus aureus under vancomycin selective pressure: the role of the small-colony variant phenotype.

Author information

1
Laboratory for Antimicrobial Pharmacodynamics, NYS Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, Buffalo, New York, USA School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
2
Institute of Medical Microbiology, University of Munster, Munster, Germany.
3
School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
4
Laboratory for Antimicrobial Pharmacodynamics, NYS Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, Buffalo, New York, USA School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA btsuji@buffalo.edu.

Abstract

Staphylococcus aureus small-colony variants (SCVs) often persist despite antibiotic therapy. Against a 10(8)-CFU/ml methicillin-resistant S. aureus (MRSA) (strain COL) population of which 0%, 1%, 10%, 50%, or 100% was an isogenic hemB knockout (Ia48) subpopulation displaying the SCV phenotype, vancomycin achieved maximal reductions of 4.99, 5.39, 4.50, 3.28, and 1.66 log10 CFU/ml over 48 h. Vancomycin at ≥16 mg/liter shifted a population from 50% SCV cells at 0 h to 100% SCV cells at 48 h, which was well characterized by a Hill-type model (R2>0.90).

PMID:
25451045
PMCID:
PMC4335873
DOI:
10.1128/AAC.04508-14
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center